NCT04909164View on ClinicalTrials.gov

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients

Active, not recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

July 30, 2025

Study Completion Date

December 1, 2025

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Immunnotherapy group

Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Trial Locations (1)

135-710

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

All Listed Sponsors
collaborator

National Evidence-Based Healthcare Collaborating Agency

OTHER_GOV

lead

Samsung Medical Center

OTHER